Pfizer is taking a novel tactic in its approach to the Russian war against Ukraine as CEO Albert Bourla told staffers on Wednesday that the company is putting its first ...

In September, Moderna received FDA emergency use authorization for its BA.4/BA.5-targeting bivalent booster vaccine, mRNA-1273.222, based on preclinical data for the shot as well as Phase II/III ...

As only about 11% of Americans have so far received the bivalent booster shots from Pfizer and Moderna, and only 30% of those over 65 years of age, the Biden ...

The next generation of Operation Warp Speed is coming soon, and this time it's going to take aim at rare diseases, Peter Marks, the director of the FDA's Center for ...

Rybelsus, Novo Nordisk’s GLP-1 also known as semaglutide, snagged a label update from the FDA, allowing patients to take it as a first-line treatment for Type II diabetes in 7 ...

Confirmed monkeypox cases in the US have now surpassed 300, and as a result, the Department of Health and Human Services is making hundreds of thousands of Bavarian Nordic’s vaccine ...

B Capital, an investment firm co-founded by Eduardo Saverin of Facebook fame, has closed its inaugural healthcare fund. Add that to its capital growth fund, and B Capital says it ...

The FDA recently added a new warning and precaution to the label of Horizon's blockbuster monoclonal antibody Tepezza (teprotumumab-trbw), which is used as a treatment for thyroid eye disease, to ...

Below are notable updates from the American Academy of Dermatology’s annual meeting over the weekend: Sanofi amends trial protocol Sanofi has big plans for amlitelimab, the monoclonal antibody ...

Pfizer and Astellas are gunning to add a fourth indication to their cancer drug Xtandi with Phase III trial results released today. The study, looking at ...

After its Covid-19 vaccine candidate petered out, CureVac earlier this month filed suit against BioNTech in German court, stating that CureVac should be compensated for the alleged infringement of ...

LinusBio, a Mount Sinai spinoff starting out focused on neurological disorders like autism, announced Thursday it raised $16 million in Series A funding. Proceeds will go toward building its ...